Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.60 |
| ▸ | TNFRSF1A | P19438 | 6/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.42 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040741 | 0.90 | ERN1 (0.61) | ERN1TNFRSF1ATLR2TLR1TLR6 | |
| SCHEMBL5560733 | 0.87 | TNFRSF1A (0.57) | ERN1TNFRSF1ARPS6KB2KDM4EMEN1 | |
| SCHEMBL6744773 | 0.80 | ERN1 (0.58) | ERN1TNFRSF1ARPS6KB2KDM4EALDH1A1 | |
| SCHEMBL5559926 | 0.79 | ERN1 (0.49) | ERN1TNFRSF1AKDM4EALDH1A1MAPT | |
| SCHEMBL2780877 | 0.78 | RPS6KB2 (0.56) | ERN1TNFRSF1ARPS6KB2KDM4EMEN1 | |
| SCHEMBL6040532 | 0.78 | TNFRSF1A (0.67) | ERN1TNFRSF1AMAPT | |
| SCHEMBL6040567 | 0.78 | TNFRSF1A (0.49) | ERN1TNFRSF1AALDH1A1GAAMAPT | |
| SCHEMBL6040715 | 0.78 | TNFRSF1A (0.61) | TNFRSF1A | |
| SCHEMBL6040711 | 0.78 | TNFRSF1A (0.61) | TNFRSF1A | |
| SCHEMBL6040725 | 0.77 | ERN1 (0.50) | ERN1TNFRSF1ARPS6KB2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108094-A2 | SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | ERN1 1752/4885TNFRSF1A 3846/4885TRIM24 4717/4885 |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | ERN1 2156/4885TNFRSF1A 3941/4885TRIM24 4807/4885 |
| US-20040181075-A1 | Process of making chalcone derivatives | CYP2B6, LSS, CYP2E1 | ERN1 2696/4885TNFRSF1A 3023/4885TRIM24 4453/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | ERN1 2156/4885TNFRSF1A 3941/4885TRIM24 4807/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ERN1 1076/4885TNFRSF1A 3877/4885TRIM24 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.